Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00171522 · ClinicalTrials.gov registry record · Phase 4
Preference of Tegaserod vs. PEG 3350 in Patients With Constipation
A Phase 4 study of Constipation, sponsored by Novartis.
- Completed
- Registry status
- Phase 4
- Development phase
- 52
- Enrollment target
- 14
- Study locations
NCT00171522 is a Phase 4 study of Constipation that has completed, run by Novartis. The registered enrollment target is 52 participants, below the 204-participant average among 54 other Constipation trials with a reported enrollment target (75% lower). The trial reports 14 study locations across 11 states.
The verdict
NCT00171522, a Phase 4 study of Constipation, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 52 participants
- Enrollment target
- 14
- Study locations
Study Summary
To determine whether female patients have a preference for tegaserod of PEG 3350 relative to dosage form, convenience, ease of administration and taste
Conditions Studied
Interventions
- DRUG Tegaserod and Polyethylene Glycol 3350
Study Locations (14)
Arizona
- Harmony Clinical Research - Oro Valley
- Central Phoenix Medical Clinic, LLC - Phoenix
- Adobe Gastroenterology, PC - Tucson
Virginia
- National Clinical Research, Inc - Richmond
- East Coast Clinical Research - Virginia Beach
California
- Associated Pharmaceutical Research Center, Inc - Buena Park
Florida
- Clinical Trial Management of Boca Raton, Inc. - Boca Raton
Kansas
- Health Science Center - Pratt
Massachusetts
- Beth Israel Deacon Medical Center - Boston
Nebraska
- Heartland Clinical Research, Inc - Omaha
New Jersey
- MBS Clinical Research, LLC - Margate City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2005-05 |
| Est. Completion | 2005-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00171522
The ClinicalTrials.gov registry entry for NCT00171522 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 204-participant average among 54 other Constipation trials with a reported enrollment target (75% lower). The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Constipation appearing as the primary indexed condition, and to 1 intervention - of which Tegaserod and Polyethylene Glycol 3350 is the first listed.
NCT00171522 reports 14 study locations spanning 11 distinct geographic areas - top geographies include Arizona, Virginia, California.
Frequently Asked Questions
What is clinical trial NCT00171522 about?
NCT00171522 is a clinical study titled "Preference of Tegaserod vs. PEG 3350 in Patients With Constipation". To determine whether female patients have a preference for tegaserod of PEG 3350 relative to dosage form, convenience, ease of administration and taste
What is the current status of trial NCT00171522?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 52 participants. The study started on 2005-05. Estimated completion is 2005-09.
What conditions does trial NCT00171522 study?
This clinical trial studies the following conditions: Constipation.
What interventions are being tested in trial NCT00171522?
The interventions under investigation include: Tegaserod and Polyethylene Glycol 3350 (DRUG).
Who is sponsoring clinical trial NCT00171522?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00171522 being conducted?
This trial has 14 study locations across Arizona, California, Florida, Kansas, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Constipation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pre-operative Polyethylene Glycol 3350 for Minimally Invasive Urogynecologic Surgery
RECRUITING · Phase 4
-
Evaluation of Fecal Microbiome Changes After Antegrade Continence Enema Placement and Initiation of Bowel Flush Regimen
RECRUITING · Phase 4
-
Preop Laxatives in Robotic Urologic Surgery
RECRUITING · Phase 4
-
Extended Use of Polyethyleneglycol3350 Laxative in Constipated Patients
COMPLETED · Phase 4
-
An Open Label Study of Chronic Polyethyleneglycol3350 Use in Constipated Patients
COMPLETED · Phase 4
-
Comparison of PolyethyleneGlycol and Placebo for Relief of Constipation From Constipating Medications
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.